Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression

Endocrine-Related Cancer

Volumn 18, Issue 4, 2011, Pages 505-517

  Shiota, Masaki ^a   Takeuchi, Ario ^a   Song, YooHyun ^a   Yokomizo, Akira ^a   Kashiwagi, Eiji ^a   Uchiumi, Takeshi ^a   Kuroiwa, Kentaro ^a   Tatsugami, Katsunori ^a   Fujimoto, Naohiro ^b   Oda, Yoshinao ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; Y BOX BINDING PROTEIN 1;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TREATMENT FAILURE; UP-REGULATION; Y-BOX-BINDING PROTEIN 1;

EID: 80052161751     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0017     Document Type: Article

References (38)

1. Allred DC, Harvey JM, Berardo M & Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11 155-168.
2. Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V et al. 2009 The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 28 2406-2418. (doi:10.1038/onc.2009.81)
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
4. Debes JD & Tindall DJ 2002 The role of androgens and the androgen receptor in prostate cancer. Cancer Letters 187 1-7. (doi:10.1016/S0304-3835(02) 00413-5)
5. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
6. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K & Dunn SE 2010 The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44(+) cells. Oncogene 29 6294-6300. (doi:10.1038/onc.2010.365)
7. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D et al. 2008 Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Molecular Cancer Therapeutics 7 59-70. (doi:10.1158/1535-7163.MCT-07-0329)
8. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ et al. 2009 Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15 402-415. (doi:10.1016/j.ccr.2009.03.017)
9. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C et al. 2009 Profiling YB-1 target genes uncovers a new mechanism for MET regulation in normal and malignant human mammary cells. Oncogene 28 1421-1431. (doi:10.1038/onc.2008.485)
10. Giménez-Bonafé P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME & Nelson CC 2004 YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59 337-349. (doi:10.1002/pros.20023)
11. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
12. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008- 5472.CAN-08-3795)
13. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al. 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69 16-22. (doi:10.1158/0008-5472.CAN-08-2764)
14. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K et al. 2009 QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Research 11 R25. (doi:10.1186/bcr2252)
15. Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE & Bally MB 2010 Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene 29 6343-6356. (doi:10.1038/onc.2010.366)
16. Kohno K, Izumi H, Uchiumi T, Ashizuka M & Kuwano M 2003 The pleiotrophic functions of the Y-box-binding protein, YB-1. BioEssays 25 691-698. (doi:10.1002/bies.10300)
17. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K &Kuwano M 1997 Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Letters 417 390-394. (doi:10.1016/S0014-5793(97)01296-9)
18. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB & Yung WK 2005 Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Molecular Cancer Therapeutics 4 1681-1688. (doi:10.1158/1535-7163.MCT-05-0258)
19. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H & Kohno K 2003 The basic and clinical implications of ABC transporters, Y-box binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Science 94 9-14. (doi:10.1111/j.1349-7006.2003.tb01344.x)
20. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H et al. 2004 The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Molecular Cancer Therapeutics 3 1485-1492.
21. Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ et al. 2010 Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS ONE 5 e12661. (doi:10.1371/journal.pone.0012661)
22. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555.
23. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH &Hannon GJ 1999 Twist is a potential oncogene that inhibits apoptosis. Genes and Development 13 2207-2217. (doi:10.1101/gad.13.17. 2207)
24. Olson EN & Klein WH 1994 bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes and Development 8 1-8. (doi:10.1101/gad.8.1.1)
25. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 8253-8261. (doi:10.1200/JCO.2005.03.4777)
26. Sharifi N, Gulley JL & Dahut WL 2010 An update on androgen deprivation therapy for prostate cancer. Endocrine-Related Cancer 17 R305-R315. (doi:10.1677/ERC-10-0187)
27. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S & Kohno K 2008 Twist promotes tumor cell growth through YB-1 expression. Cancer Research 68 98-105. (doi:10.1158/0008-5472.CAN-07-2981)
28. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2010a Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237-250. (doi:10.1038/onc.2009.322)
29. Shiota M, Song Y, Yokomizo A, Tada Y, Kuroiwa K, Eto M, Oda Y, Inokuchi J, Uchiumi T, Fujimoto N et al. 2010b Human heterochromatin protein 1 isoform HP1β enhances androgen receptor activity and is implicated in prostate cancer growth. Endocrine-Related Cancer 17 455-467. (doi:10.1677/ERC-09-0321)
30. Shiota M, Yokomizo A, Tada Y, Uchiumi T, Inokuchi J, Tatsugami K, Kuroiwa K, Yamamoto K, Seki N &Naito S 2010c P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Science 101 1797-1806. (doi:10.1111/j.1349- 7006.2010.01598.x)
31. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP & Dunn SE 2008 Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Research 10 R99. (doi:10.1186/bcr2202)
32. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al. 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 120 2715-2730. (doi:10.1172/JCI41824)
33. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M et al. 2005 Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24 4281-4292. (doi:10.1038/sj.onc.1208590)
34. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL et al. 2010 Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Research 70 2840-2851. (doi:10.1158/0008-5472.CAN-09-3155)
35. Tomura A, Goto K, Morinaga H, Nomura M, Okabe T, Yanase T, Takayanagi R & Nawata H 2001 The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. Journal of Biological Chemistry 276 28395-28401. (doi:10.1074/jbc.M101755200)
36. Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Tatsugami K, Inokuchi J, Takeuchi A & Naito S 2011 Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 71 298-304. (doi:10.1002/pros.21243)
37. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB et al. 2005 Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Molecular Cancer Therapeutics 4 1146-1156. (doi:10.1158/1535-7163.MCT-05-0078)
38. Zegarra-Moro OL, Schmidt LJ, Huang H & Tindall DJ 2002 Disruption of androgen function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62 1008-1013.